Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers.

Xiao-Yan ShengYan LiangXue-Yuan YangLi-E LiXia YeXia ZhaoYi Min Cui

Published in: European journal of clinical pharmacology (2019)

Remimazolam was safe and well tolerated in healthy Chinese participants. Based on the phase I clinical study, we suggest that remimazolam besylate demonstrates greater sedation and quicker recovery from sedation than midazolam.

Keyphrases

mechanical ventilation
low dose
clinical trial
acute respiratory distress syndrome
pulmonary hypertension